Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
February 24, 2005 | VP of Regulatory Affairs | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
February 24, 2005 | VP of Regulatory Affairs | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
March 23, 2011 | CMO | Form 4 | Conversion of derivative security | 6 | -- | -- | |
January 14, 2011 | Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 6 | $1,197.80 | 6 | |
March 23, 2011 | CFO | Form 4 | Conversion of derivative security | 8 | -- | -- | |
March 23, 2011 | Controller & CAO | Form 4 | Conversion of derivative security | 8 | -- | -- | |
January 14, 2011 | CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 8 | $1,197.80 | 8 | |
January 14, 2011 | Controller & CAO | Form 4 | Open market or private purchase of non-derivative or derivative security | 8 | $1,197.80 | 8 | |
March 23, 2011 | Director | Form 4 | Conversion of derivative security | 12 | -- | -- | |
January 14, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 12 | $1,197.80 | 12 | |
August 9, 2011 | Director | Form 4 | Conversion of derivative security | 41 | -- | -- | |
March 23, 2011 | CEO | Form 4 | Conversion of derivative security | 41 | -- | -- | |
January 14, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 41 | $1,197.80 | 41 | |
January 14, 2011 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 41 | $1,197.80 | 41 | |
March 23, 2011 | Director | Form 4 | Conversion of derivative security | 83 | -- | -- | |
January 14, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 83 | $1,197.80 | 83 | |
September 10, 2012 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 100 | $4.94 | 69,587 | |
September 22, 2010 | Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 100 | $3.04 | 28,187 | |
November 17, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 100 | $2.60 | 113,462 | |
December 5, 2011 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 200 | $2.20 | 164,188 | |
March 20, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4 | Open market or private purchase of non-derivative or derivative security | 200 | $4.19 | 2,000 | |
March 14, 2006 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 200 | $4.05 | 200 | |
March 14, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4/A | Open market or private purchase of non-derivative or derivative security | 200 | $4.05 | 200 | |
June 16, 2008 | Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300 | $4.39 | 27,367 | |
June 16, 2008 | Director, President & CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 300 | $4.39 | 27,367 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.